Dianthus Therapeutics Shares Outstanding History (DNTH)
Dianthus Therapeutics reported 43.2M shares outstanding at the end of fiscal 2025.
View full Dianthus Therapeutics company overviewDianthus Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 43.2M | 12.1M | +38.91% |
| 2024 | 2024-12-31 | 31.1M | 16.3M | +109.99% |
| 2023 | 2023-12-31 | 14.8M | 13.9M | +1592.91% |
| 2022 | 2022-12-31 | 875,279 | −2.8M | −76.18% |
| 2021 | 2021-12-31 | 3.7M | 641,626.375 | +21.15% |
| 2020 | 2020-12-31 | 3.0M | 579,537.688 | +23.62% |
| 2019 | 2019-12-31 | 2.5M | 372,218.688 | +17.88% |
| 2018 | 2018-12-31 | 2.1M | 1.9M | +1316.48% |
| 2017 | 2017-12-31 | 146,952.938 | — | — |
Dianthus Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 54.8M | 22.6M | +70.31% |
| Q1 2026 | 2026-03-31 | 54.6M | 22.5M | +69.90% |
| Q4 2025 | 2025-12-31 | 43.2M | 12.1M | +38.91% |
| Q3 2025 | 2025-09-30 | 42.9M | 13.5M | +45.93% |
| Q2 2025 | 2025-06-30 | 32.2M | 2.8M | +9.62% |
| Q1 2025 | 2025-03-31 | 32.1M | 2.8M | +9.46% |
| Q4 2024 | 2024-12-31 | 31.1M | 16.3M | +109.99% |
| Q3 2024 | 2024-09-30 | 29.4M | 14.5M | +98.18% |
| Q2 2024 | 2024-06-30 | 29.4M | 25.6M | +674.31% |
| Q1 2024 | 2024-03-31 | 29.3M | 25.6M | +674.26% |
| Q4 2023 | 2023-12-31 | 14.8M | 11.0M | +290.97% |
| Q3 2023 | 2023-09-30 | 14.8M | 11.0M | +291.52% |
| Q2 2023 | 2023-06-30 | 3.8M | 115,815 | +3.15% |
| Q1 2023 | 2023-03-31 | 3.8M | 115,604 | +3.15% |
| Q4 2022 | 2022-12-31 | 3.8M | 115,047 | +3.13% |
| Q3 2022 | 2022-09-30 | 3.8M | 111,140.563 | +3.03% |
| Q2 2022 | 2022-06-30 | 3.7M | 18,151.375 | +0.50% |
| Q1 2022 | 2022-03-31 | 3.7M | 637,247 | +20.98% |
| Q4 2021 | 2021-12-31 | 3.7M | 641,626.375 | +21.15% |
| Q3 2021 | 2021-09-30 | 3.7M | 655,237.625 | +21.71% |
| Q2 2021 | 2021-06-30 | 3.7M | 641,720.188 | +21.28% |
| Q1 2021 | 2021-03-31 | 3.0M | 571,785.625 | +23.19% |
| Q4 2020 | 2020-12-31 | 3.0M | 579,537.688 | +23.62% |
| Q3 2020 | 2020-09-30 | 3.0M | 584,421.875 | +24.01% |
| Q2 2020 | 2020-06-30 | 3.0M | 595,647.125 | +24.62% |
| Q1 2020 | 2020-03-31 | 2.5M | 367,041.25 | +17.49% |
| Q4 2019 | 2019-12-31 | 2.5M | 372,218.688 | +17.88% |
| Q3 2019 | 2019-09-30 | 2.4M | 365,034.5 | +17.64% |
| Q2 2019 | 2019-06-30 | 2.4M | 363,862.625 | +17.70% |
| Q1 2019 | 2019-03-31 | 2.1M | 2.0M | +1328.26% |
| Q4 2018 | 2018-12-31 | 2.1M | — | — |
| Q3 2018 | 2018-09-30 | 2.1M | — | — |
| Q2 2018 | 2018-06-30 | 2.1M | — | — |
| Q4 2017 | 2017-12-31 | 146,952.938 | — | — |
Dianthus Therapeutics shares outstanding trends
Over the last five reported fiscal years, Dianthus Therapeutics's shares outstanding moved from 3.0M to 43.2M, a change of 40.2M. The latest reported quarter, Q2 2026, shows 54.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dianthus Therapeutics filings at SEC.gov ↗